Predictive modelling for high-risk stage II colon cancer using auto-artificial intelligence

被引:1
|
作者
Ishizaki, Tetsuo [1 ]
Mazaki, Junichi [1 ]
Enomoto, Masanobu [1 ]
Udo, Ryutaro [1 ]
Tago, Tomoya [1 ]
Kasahara, Kenta [1 ]
Nagakawa, Yuichi [1 ]
机构
[1] Tokyo Med Univ, Dept Gastrointestinal & Pediat Surg, Shinjuku Ku, 6-7-1 Nishi, Tokyo 1600023, Japan
关键词
Predictive modelling; Stage II colon cancer; High-risk; Auto-artificial intelligence; Prediction; Adjuvant chemotherapy; ADJUVANT CHEMOTHERAPY; CONTROLLED-TRIAL; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; GUIDELINES; THERAPY; SOCIETY;
D O I
10.1007/s10151-022-02685-y
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Recently, stratification of high-risk stage II colon cancer (CC) and the need for adjuvant chemotherapy have been the focus of attention. The aim of this retrospective study was to define high-risk factors for recurrent stage II CC using Prediction One auto-artificial intelligence (AI) software and develop a new predictive model for high-risk stage II CC. Methods The study included 259 consecutive pathological stage II CC patients undergoing curative resection at our institution between January 2000 and December 2016. Prediction One software with five-fold cross-validation was used to create a predictive model and receiver operating characteristic (ROC) curve. Predictive accuracy of AI was evaluated using the area under the ROC curve (AUC). We also evaluated the importance of variables (IOV) using a method based on permutation feature importance (IOV > 0.01 defined high-risk factors) to evaluate disease-free survival (DFS). Results The median observation period was 6.1 (range = 0.3-15.8) years. Thirty-seven patients had recurrence (14.3%); the AUC of the AI model was 0.775. Preoperative carcinoembryonic antigen > 5.0 ng/mL (IOV = 0.047), venous invasion (IOV = 0.014), and obstruction (IOV = 0.012) were high-risk factors contributing to cancer recurrence. Patients with 2-3 high-risk factors had lower 5-year DFS than those with 0-1 factor (87.4% vs 62.7%, p < 0.001). Conclusions We developed a new predictive model that could predict recurrent high-risk stage II CC with high probability using auto-AI Prediction One software. Patients with >= 2 of the aforementioned factors are considered to have high risks for recurrent stage II CC and may benefit from adjuvant chemotherapy.
引用
收藏
页码:183 / 188
页数:6
相关论文
共 50 条
  • [21] Left colon as a novel high-risk factor for postoperative recurrence of stage II colon cancer
    Wang, Liming
    Hirano, Yasumitsu
    Ishii, Toshimasa
    Kondo, Hiroka
    Hara, Kiyoka
    Obara, Nao
    Yamaguchi, Shigeki
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2020, 18 (01)
  • [22] Identification of patients with high-risk stage II colon cancer for adjuvant therapy
    Quah, Hak-Mien
    Chou, Joanne F.
    Gonen, Mithat
    Shia, Jinru
    Schrag, Deborah
    Landmann, Ron G.
    Guillem, Jose G.
    Paty, Philip B.
    Temple, Larissa K.
    Wong, W. Douglas
    Weiser, Martin R.
    DISEASES OF THE COLON & RECTUM, 2008, 51 (05) : 503 - 507
  • [23] Adjuvant chemotherapy for stage II colon cancer: the prognostic value of high-risk features
    Cheong, C.
    Suh, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [24] The Role of Anastomotic Leak as a Potential High-Risk Criteria in Stage II Colon Cancer
    Behman, Ramy
    Coburn, Natalie
    Ashamalla, Shady
    Perera, Sheron
    Mahar, Alyson
    Jeong, Irene
    Hallet, Julie
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S85 - S86
  • [25] Is Microsatellite Status Associated With Prognosis in Stage II Colon Cancer With High-Risk Features?
    Cavallaro, Paul M.
    Stafford, Caitlin
    Cauley, Christy E.
    Berger, David L.
    Bordeianou, Liliana
    Kunitake, Hiroko
    Francone, Todd
    Ricciardi, Rocco
    DISEASES OF THE COLON & RECTUM, 2021, 64 (05) : 545 - 554
  • [26] Evaluation of the efficacy of adjuvant chemotherapy in patients with high-risk stage II colon cancer
    Cakar, B.
    Varol, U.
    Junushova, B.
    Muslu, U.
    Oner, P. Gursoy
    Surmeli, Z. Gokhan
    Cirak, Y.
    Karaca, B.
    Sezgin, C.
    Karabulut, B.
    Uslu, R.
    JOURNAL OF BUON, 2013, 18 (02): : 372 - 376
  • [27] High-risk groups of patients with stage II colon carcinoma
    Merkel, S
    Wein, A
    Günther, K
    Papadopoulos, T
    Hohenberger, W
    Hermanek, P
    CANCER, 2001, 92 (06) : 1435 - 1443
  • [28] Tumor budding as an index to identify high-risk patients with stage II colon cancer
    Nakamura, Takatoshi
    Mitomi, Hiroyuki
    Kanazawa, Hideki
    Ohkura, Yasuo
    Watanabe, Masahiko
    DISEASES OF THE COLON & RECTUM, 2008, 51 (05) : 568 - 572
  • [29] Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer
    Zunder, Stephanie M.
    van Pelt, Gabi W.
    Gelderblom, Hans J.
    Mancao, Christoph
    Putter, Hein
    Tollenaar, Rob A.
    Mesker, Wilma E.
    BRITISH JOURNAL OF CANCER, 2018, 119 (02) : 164 - 169
  • [30] Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer
    Stéphanie M. Zunder
    Gabi W. van Pelt
    Hans J. Gelderblom
    Christoph Mancao
    Hein Putter
    Rob A. Tollenaar
    Wilma E. Mesker
    British Journal of Cancer, 2018, 119 : 164 - 169